Latest News

• share
• favorite_border

An experimental gene therapy that turns a patient's own blood cells into cancer killers worked in a major study. Article by the Associated Press.

• share
• favorite_border

Led by associate professor of pathology and Yale Cancer Center member Don Nguyen, PhD, the researchers analyzed RNA from patients with disease that was limited to the lungs as well as cancers that had spread.

• share
• favorite_border

Susan Baserga selected as a finalist for the 2017 Connecticut Technology Council Women of Innovation program

• share
• favorite_border

Dr. Cary Gross, a professor of medicine and cancer researcher at Yale University School of Medicine discusses his 80-year-old father's diagnosis with Hodgkin’s disease.

• share
• favorite_border

Four Yale School of Medicine researchers have been elected to the prestigious Connecticut Academy of Science and Engineering (CASE).

• share
• favorite_border

The Connecticut Academy of Science and Engineering has elected 24 of the state’s leading experts in science, engineering, and technology to membership in the academy, including 11 new members from Yale.

• share
• favorite_border

In a new study, Yale researchers identified genetic abnormalities that mark atypical meningiomas, which have a 40% chance of recurring after surgical removal and are marked by a shorter survival rate than benign tumors.

• share
• favorite_border

A recent Yale study may have found a new way to fight brain cancer.

• share
• favorite_border

An analysis of a patient’s deadly brain tumor helped doctors at Smilow Cancer Hospital identify new emerging mutations and keep a 55-year old woman alive for more than five years, researchers report in the journal Genome Medicine.

• share
• favorite_border

The board of directors for World Conference on Interventional Oncology, a nonprofit association that supports and promotes the field, has established a society to further its mission.

• share
• favorite_border

Immunotherapy has been a game changer for the oncology field, but typical models used to assess the value of cancer treatments don’t take into account the unique characteristics of this therapy, according to experts at the 2016 annual meeting of the Society for Immunotherapy of Cancer (SITC).

• share
• favorite_border

Yale researchers found in a study that one in four high schoolers who use electronic cigarettes are inhaling vapors produced by dripping e-liquids directly onto heating coils, instead of inhaling from the e-cigarette mouthpiece, possibly increasing exposure to toxins and nicotine.

• share
• favorite_border

A rare look at brain surgery with the patient alert and awake at Smilow Cancer Hospital at Yale-New Haven.

• share
• favorite_border

In a new study, Yale Cancer Center researchers identified a novel genetic defect that prevents brain tumor cells from repairing damaged DNA.

• share
• favorite_border

In a second human case, a Yale-led research team has found that a melanoma cell and a white blood cell can fuse to form a hybrid with the ability to metastasize. The finding provides further insight into how melanoma and other cancers spread from solid tumors with implications for future treatment.

• share
• favorite_border

• share
• favorite_border

Dr. Harold Tara Appointed Medical Director of Smilow Care Centers in Trumbull & Fairfield

• share
• favorite_border

• share
• favorite_border

• share
• favorite_border

• share
• favorite_border

• share
• favorite_border

Recognizing a critical need to improve national vaccination rates for the human papillomavirus (HPV), Yale Cancer Center has again united with each of the 69 National Cancer Institute (NCI)-designated cancer centers in issuing a joint statement in support of recently revised recommendations from the Centers for Disease Control and Prevention (CDC).

• share
• favorite_border

• share
• favorite_border

The Connecticut Region of the National Organization of Italian American Women (NOIAW) will honor three of Connecticut’s most prominent and pioneering women at its eighth annual Epiphany Celebration brunch and silent auction event, on Sunday, January 15, 2017, at the New Haven Lawn Club in New Haven, CT.

• share
• favorite_border

• share
• favorite_border

In a Yale-led study, Qin Yan and his co-authors focused on a family of enzymes — known as KDM5 — that have been shown in previous studies to be involved in cancer cell growth and spreading.

• share
• favorite_border

The regular use of aspirin lowers the risk for pancreatic cancer by almost 50 percent, a new study in China led by the Yale School of Public Health finds.

• share
• favorite_border

A new Yale study suggests that patients with a common form of lung cancer may still benefit from delayed chemotherapy started up to four months after surgery, according to the researchers.

• share
• favorite_border

• share
• favorite_border

Human papillomavirus-positive oropharynx cancers (cancers of the tonsils and back of the throat) are on rise. After radiation treatment, patients often experience severe, lifelong swallowing, eating, and nutritional issues. However, new clinical trial research shows reducing radiation for some patients with HPV-associated oropharyngeal squamous cell carcinomas can maintain high cure rates while sparing some of these late toxicities.

• share
• favorite_border

Researchers at Yale Cancer Center and Yale Medicine have identified the critical target of new immune-checkpoint therapies: subsets of immune cells called tissue resident memory (TRM) T cells. In the same research, scientists also found that individual metastatic cancer lesions contain unique sets of TRM cells.

• share
• favorite_border

Regular use of aspirin by people living in Shanghai, China, was associated with decreased risk for developing pancreatic cancer, according to data published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.

• share
• favorite_border

• share
• favorite_border

Researchers at Yale Cancer Center have identified a new subtype of triple negative breast cancer that shows significantly improved response to chemotherapy.

• share
• favorite_border

• share
• favorite_border

A Yale Cancer Center team has evaluated the use of hypomethylating agents in patients suffering from Acute Myeloid Leukemia (AML) who were resistant to treatment with intensive chemotherapy.

• share
• favorite_border

Doctors at Yale believe immunotherapy is causing a new type of acute-onset diabetes, with at least 17 cases so far.

• share
• favorite_border

In a recent study, a Yale Cancer Center team confirmed expectations of higher healthcare utilization and costs with relapsed Diffuse Large B-Cell Lymphoma (DLBCL).

• share
• favorite_border

The American Cancer Society (ACS), the largest non-government, not-for-profit funding source of cancer research in the United States, has approved funding for three new research grants totaling over $1.7 million to investigators at Yale University.

• share
• favorite_border

A new drug has been approved by the FDA in the fight against lung cancer. Tecentriq is being used by patients like Cornelius Bresnan, who had late-stage cancer.

• share
• favorite_border

Lung-MAP (SWOG S1400) is a multi-drug, multi-sub-study, biomarker-driven squamous cell lung cancer clinical trial that uses state-of-the-art genomic profiling to match patients to sub-studies testing investigational treatments that may target the genomic alterations, or mutations, found to be driving the growth of their cancer.

• share
• favorite_border

Professor Roy S. Herbst, M.D., Ph.D., Yale University, New Haven, will be recognized by The International Association for the Study of Lung Cancer with a Distinguished Award at the IASLC 17th World Conference on Lung Cancer in Vienna, Austria.

• share
• favorite_border

• share
• favorite_border

Immunotherapy continues to revolutionize the field of non–small cell lung cancer (NSCLC), with researchers now focusing on the optimal use of immune agents in the frontline setting.

• share
• favorite_border

New data presented at a cancer conference suggests that more than three in five Australian breast cancer survivors are overweight or obese – and that it’s likely to increase their risk of cancer returning.

• share
• favorite_border

• share
• favorite_border

• share
• favorite_border

The FDA granted approval to pembrolizumab for the first-line treatment of patients with metastatic non–small cell lung cancer whose tumors express programmed death ligand-1 as determined by an FDA–approved test.

• share
• favorite_border

The recent approval of pembrolizumab (Keytruda) in recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) following progression on a platinum-based chemotherapy was a significant advancement for the disease. However, Barbara A. Burtness, MD, said, the approval of the PD-1 inhibitor only scratches the surface of the potential of immunotherapies in head and neck cancer.

• share
• favorite_border